PL362916A1 - Pochodna 3,4-dihydroizocholiny i środek farmaceutyczny zawierający ten związek jako substancję czynną - Google Patents

Pochodna 3,4-dihydroizocholiny i środek farmaceutyczny zawierający ten związek jako substancję czynną

Info

Publication number: PL362916A1
Authority: PL; Poland
Prior art keywords: compounds; active ingredient; dihydroisoquinoline derivative; drugs containing; formula
Prior art date: 2000-08-01

Application number

PL01362916A

Other languages

English (en)

Inventor

Mikio Ogawa

Yoshikazu Takaoka

Akira Ohhata

Original Assignee

Ono Pharmaceutical Co, Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-01

Filing date

2001-07-30

Publication date

2004-11-02

2001-07-30 Application filed by Ono Pharmaceutical Co, Ltd. filed Critical Ono Pharmaceutical Co, Ltd.

2004-11-02 Publication of PL362916A1 publication Critical patent/PL362916A1/pl

Links

-1 3,4-dihydroisoquinoline derivative compounds Chemical class 0.000 title abstract 2
239000004480 active ingredient Substances 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title abstract 2
239000003814 drug Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
102000009135 CB2 Cannabinoid Receptor Human genes 0.000 abstract 1
108010073376 CB2 Cannabinoid Receptor Proteins 0.000 abstract 1
206010012438 Dermatitis atopic Diseases 0.000 abstract 1
206010020751 Hypersensitivity Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
208000004550 Postoperative Pain Diseases 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
230000007815 allergy Effects 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
201000008937 atopic dermatitis Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1
239000008177 pharmaceutical agent Substances 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

PL01362916A 2000-08-01 2001-07-30 Pochodna 3,4-dihydroizocholiny i środek farmaceutyczny zawierający ten związek jako substancję czynną PL362916A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2000232911		2000-08-01
PCT/JP2001/006541 WO2002010135A1 (en)	2000-08-01	2001-07-30	3,4-dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient

Publications (1)

Publication Number	Publication Date
PL362916A1 true PL362916A1 (pl)	2004-11-02

Family

ID=18725515

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL01362916A PL362916A1 (pl)	2000-08-01	2001-07-30	Pochodna 3,4-dihydroizocholiny i środek farmaceutyczny zawierający ten związek jako substancję czynną

Country Status (20)

Country	Link
US (1)	US6956033B2 (pl)
EP (1)	EP1306373B1 (pl)
JP (1)	JP4982937B2 (pl)
KR (1)	KR20030017660A (pl)
CN (1)	CN1466577A (pl)
AT (1)	ATE362470T1 (pl)
AU (1)	AU2001275798A1 (pl)
BR (1)	BR0112883A (pl)
CA (1)	CA2417156A1 (pl)
CZ (1)	CZ2003284A3 (pl)
DE (1)	DE60128476D1 (pl)
HU (1)	HUP0303070A2 (pl)
IL (1)	IL154082A0 (pl)
MX (1)	MXPA03000952A (pl)
NO (1)	NO20030490L (pl)
NZ (1)	NZ523839A (pl)
PL (1)	PL362916A1 (pl)
RU (1)	RU2272030C2 (pl)
WO (1)	WO2002010135A1 (pl)
ZA (1)	ZA200300619B (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003061699A1 (en) *	2001-12-27	2003-07-31	Japan Tobacco, Inc.	Remedies for allergic diseases
TW200302726A (en) *	2002-01-31	2003-08-16	Ono Pharmaceutical Co	Nitrogen-containing bicyclic compound and medicament containing same as active ingredient
WO2003075917A1 (en)	2002-03-08	2003-09-18	Signal Pharmaceuticals, Inc.	Combination therapy for treating, preventing or managing proliferative disorders and cancers
EP1661572A1 (en) *	2003-08-18	2006-05-31	Shionogi & Co., Ltd.	Novel use of cannabinoid receptor agonist
TW200533657A (en) *	2004-02-17	2005-10-16	Esteve Labor Dr	Substituted pyrazoline compounds, their preparation and use as medicaments
AR051596A1 (es) *	2004-10-26	2007-01-24	Irm Llc	Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
TWI360539B (en) *	2004-10-28	2012-03-21	Shionogi & Co	3-carbamoyl-2-pyridone derivatives
AU2005316739A1 (en) *	2004-12-13	2006-06-22	Galileo Pharmaceuticals, Inc.	Spiro derivatives as lipoxygenase inhibitors
US20060160850A1 (en)	2005-01-18	2006-07-20	Chongqing Sun	Bicyclic heterocycles as cannabinoid receptor modulators
EP1743892A1 (en) *	2005-07-15	2007-01-17	Laboratorios del Dr. Esteve S.A.	Substituted pyrazoline compounds, their preparation and use as medicaments
US7897589B2 (en) *	2005-07-15	2011-03-01	Laboratorios Del Dr. Esteve, S.A.	Substituted pyrazoline compounds, their preparation and use as medicaments
EP1757587A1 (en) *	2005-07-15	2007-02-28	Laboratorios Del Dr. Esteve, S.A.	Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743890A1 (en) *	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
BRPI0706365A2 (pt) *	2006-01-06	2011-03-22	Sepracor Inc	Cicloalquilaminas como inibidores da recaptação de monoamina
KR101373087B1 (ko) *	2006-10-30	2014-03-11	산메디카루 가부시키가이샤	치과용 셀프 에칭 프라이머 조성물
RU2326114C1 (ru) *	2006-11-20	2008-06-10	Государственное учреждение Институт технической химии Уральского отделения Российской академии наук (ИТХ УрО РАН)	Способ получения 1-замещенных 3,3,4,4-тетраметил-3,4-дигидроизохинолинов
WO2008088744A1 (en) *	2007-01-17	2008-07-24	Merck & Co., Inc.	Decahydroquinoline analogs as cb2 receptor modulators
US20100130603A1 (en)	2007-03-09	2010-05-27	Kyoto University	Medicament for prophylactic and therapeutic treatment of dermatosis resulting from excessively advanced keratinization
RU2374232C1 (ru) *	2008-07-04	2009-11-27	Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет"	(2z,5z)-1-арил-3-гидрокси-5-(3,3-диметил-3,4-дигидроизохинолин-1(2н)-илиден)-пент-2-ен-1,4-дионы и способ их получения
EP2151234A1 (en) *	2008-07-28	2010-02-10	Laboratorios Del. Dr. Esteve, S.A.	Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
RU2374231C1 (ru) *	2008-11-19	2009-11-27	Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет"	(1z,3z)-4-арил-4-гидрокси-1-(3,3-диалкил-3,4-дигидроизохинолин-1(2h)-илиден)-бут-3-ен-4-оны и способ их получения
WO2010080503A1 (en) *	2008-12-19	2010-07-15	Genentech, Inc.	Heterocyclic compounds and methods of use
WO2010147133A1 (ja)	2009-06-17	2010-12-23	小野薬品工業株式会社	新規なイミダゾピリジン化合物
US20120277296A1 (en)	2009-07-23	2012-11-01	Sophie Lotersztajn	Selective CB2 Receptor Agonists for Use in the Prevention or Treatment of Alcoholic Liver Disease
ES2642586T3 (es)	2009-07-27	2017-11-16	Gilead Sciences, Inc.	Compuestos heterocíclicos condensados como moduladores de canales iónicos
RU2417221C1 (ru) *	2009-11-02	2011-04-27	Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет"	(1z,3z)-4-арил-4-гидрокси-1-(3,3-диалкил-3,4-дигидроизохинолин-1(2н)-илиден)-бут-3-ен-4-оны и способ их получения
EP2588197B1 (en)	2010-07-02	2014-11-05	Gilead Sciences, Inc.	Fused heterocyclic compounds as ion channel modulators
WO2012037349A2 (en) *	2010-09-17	2012-03-22	Glaxosmithkline Llc	Compounds
WO2012037351A1 (en) *	2010-09-17	2012-03-22	Glaxosmithkline Llc	Compounds
KR20140033377A (ko)	2011-05-10	2014-03-18	길리애드 사이언시즈, 인코포레이티드	나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
UY34171A (es)	2011-07-01	2013-01-31	Gilead Sciences Inc	Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (pl)	2011-07-01	2018-04-28
US8889675B2 (en)	2011-10-14	2014-11-18	Abbvie Inc.	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8940737B2 (en)	2011-10-14	2015-01-27	Abbvie Inc.	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP6662901B2 (ja) *	2015-03-27	2020-03-11	シンジェンタパーティシペーションズアーゲー	殺微生物性二環式複素環式誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1470084A1 (de) *	1964-08-19	1969-05-29	Merck Ag E	Verfahren zur Herstellung von substituierten Piperidin-derivaten
HU196758B (en) *	1986-05-21	1989-01-30	Gyogyszerkutato Intezet	Process for production of 3-hidroxi-methil-quinolines and medical compositions containing them
DE3718570A1 (de) *	1987-06-03	1988-12-15	Boehringer Ingelheim Kg	Benzo- und thieno-3,4-dihydro-1- pyridinylessigsaeurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5532237A (en) *	1995-02-15	1996-07-02	Merck Frosst Canada, Inc.	Indole derivatives with affinity for the cannabinoid receptor
WO1997029079A1 (en)	1996-02-06	1997-08-14	Japan Tobacco Inc.	Novel compounds and pharmaceutical use thereof
US5948777A (en)	1997-03-18	1999-09-07	Smithkline Beecham Corporation	Cannabinoid receptor agonists
FR2783246B1 (fr)	1998-09-11	2000-11-17	Aventis Pharma Sa	Derives d'azetidine, leur preparation et les medicaments les contenant

2001
- 2001-07-30 CZ CZ2003284A patent/CZ2003284A3/cs unknown
- 2001-07-30 BR BR0112883-3A patent/BR0112883A/pt not_active IP Right Cessation
- 2001-07-30 EP EP01953336A patent/EP1306373B1/en not_active Expired - Lifetime
- 2001-07-30 US US10/333,591 patent/US6956033B2/en not_active Expired - Fee Related
- 2001-07-30 CA CA002417156A patent/CA2417156A1/en not_active Abandoned
- 2001-07-30 AT AT01953336T patent/ATE362470T1/de not_active IP Right Cessation
- 2001-07-30 AU AU2001275798A patent/AU2001275798A1/en not_active Abandoned
- 2001-07-30 IL IL15408201A patent/IL154082A0/xx unknown
- 2001-07-30 PL PL01362916A patent/PL362916A1/pl unknown
- 2001-07-30 MX MXPA03000952A patent/MXPA03000952A/es unknown
- 2001-07-30 CN CNA01816496XA patent/CN1466577A/zh active Pending
- 2001-07-30 HU HU0303070A patent/HUP0303070A2/hu unknown
- 2001-07-30 RU RU2003102888/04A patent/RU2272030C2/ru not_active IP Right Cessation
- 2001-07-30 NZ NZ523839A patent/NZ523839A/en unknown
- 2001-07-30 KR KR10-2003-7001424A patent/KR20030017660A/ko not_active Withdrawn
- 2001-07-30 DE DE60128476T patent/DE60128476D1/de not_active Expired - Lifetime
- 2001-07-30 WO PCT/JP2001/006541 patent/WO2002010135A1/ja not_active Ceased
- 2001-07-30 JP JP2002516267A patent/JP4982937B2/ja not_active Expired - Fee Related
2003
- 2003-01-22 ZA ZA200300619A patent/ZA200300619B/xx unknown
- 2003-01-30 NO NO20030490A patent/NO20030490L/no unknown

Also Published As

Publication number	Publication date
CZ2003284A3 (cs)	2003-09-17
JP4982937B2 (ja)	2012-07-25
EP1306373A1 (en)	2003-05-02
WO2002010135A1 (en)	2002-02-07
NO20030490L (no)	2003-03-27
EP1306373A4 (en)	2004-09-01
IL154082A0 (en)	2003-07-31
US20040077643A1 (en)	2004-04-22
MXPA03000952A (es)	2003-09-05
CN1466577A (zh)	2004-01-07
HUP0303070A2 (hu)	2003-12-29
KR20030017660A (ko)	2003-03-03
CA2417156A1 (en)	2003-01-23
RU2272030C2 (ru)	2006-03-20
NZ523839A (en)	2005-07-29
DE60128476D1 (de)	2007-06-28
EP1306373B1 (en)	2007-05-16
ZA200300619B (en)	2004-05-20
ATE362470T1 (de)	2007-06-15
AU2001275798A1 (en)	2002-02-13
US6956033B2 (en)	2005-10-18
BR0112883A (pt)	2003-06-24
NO20030490D0 (no)	2003-01-30

Legal Events

Date	Code	Title	Description
2009-04-30	DISC	Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
ZA200300619B (en)	2004-05-20	3,4-dihyroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient.
HU9500240D0 (en)	1995-03-28	New prolin-amide derivatives and pharmaceutical compositions containing them as active component
JO2311B1 (en)	2005-09-12	Alkyl inhibitors Ariel phosphodiesterase-4
BG104441A (en)	2001-01-31	Cyclic amine derivatives and their use as drugs
NO306464B1 (no)	1999-11-08	Benzimidazolforbindelser, farmasöytiske preparater som omfatter slike forbindelser, samt anvendelse av forbindelsene for fremstilling av medikamenter
HUP0401086A3 (en)	2011-07-28	4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for preparation of pharmaceutical compositions for the treatment of pain, anxiety or gastrointestinal disorders and process for preparation the compounds
WO2005056524A3 (en)	2005-09-22	Therapeutic agents useful for treating pain
EP1236726A4 (en)	2003-01-15	TRIAZASPIRO [5.5] UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS AN ACTIVE INGREDIENT
GEP20033025B (en)	2003-07-25	4,4-Biarylpiperidine Derivatives with Opioid Receptor Activity
HUP0301167A3 (en)	2009-12-28	Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
GB9927844D0 (en)	2000-01-26	Chemical compounds
PL374325A1 (pl)	2005-10-17	Bursztyniany 5,8,14-triazatetracyklo[10.3.1.0 2,11 .0 4,9]-heksadeka-2(11),3,5,7,9-pentaenu i ich środki farmaceutyczne
WO2002024697A1 (en)	2002-03-28	Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
AU3955199A (en)	1999-12-20	Remedies for itching containing PGD2 antagonists
WO2003015780A3 (en)	2003-11-13	Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
EP1254898A4 (en)	2003-03-12	BENZO-CONDENSED HETEROCYCLIC DERIVATIVES AND THESE MEDICINES CONTAINING ACTIVE SUBSTANCES
WO2003024941A1 (en)	2003-03-27	Naphthalene compounds and use thereof as drugs
CA2278057A1 (en)	1998-07-23	Tachykinin antagonists
BG108164A (en)	2004-07-30	Glyt-1 inhibitors
HUP0302928A3 (en)	2005-03-29	Novel crystals of n-hydroxy-2(s)-methyl-5-ethoxymethoxy-4(s)-[n-(4-phenoxyphenyl-carbonyl)amino] pentanamide, process for their production and medicines containing the crystals as the active ingredient
EP1234576A4 (en)	2004-03-31	MEDICINE AGAINST EATING DISORDERS
EP1541553A4 (en)	2007-04-11	NEW INDOLIN COMPOUND AND ITS THERAPEUTIC USE
CA2239053A1 (en)	1997-06-26	Diphenyl pyridyl ethane derivatives as pde iv inhibitors
TH39271A (th)	2000-07-10	อนุพันธ์สไปโร-ไพเพอริดีน และการใช้งานของสิ่งเหล่านั้นเป็นสารอายุรเวช
KR100408626B1 (en)	2003-12-11	Pharmaceutical composition for inhibiting the activity of phosphodiesterase